Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder

American Journal of Psychiatry

Volumn 165, Issue 3, 2008, Pages 335-341

  Wilhelm, Sabine ^a   Buhlmann, Ulrike ^b   Tolin, David F ^b   Meunier, Suzanne A ^b   Pearlson, Godfrey D ^b   Reese, Hannah E ^b   Cannistraro, Paul ^b   Jenike, Michael A ^b   Rauch, Scott L ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSERINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO;

ADULT; ARTICLE; BEHAVIOR THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; HUMAN; LONG TERM POTENTIATION; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PSYCHOEDUCATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT PLANNING; ANIMAL; CASE REPORT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG POTENTIATION; FEMALE; FOLLOW UP; HOSPITALIZATION; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PSYCHOLOGICAL RATING SCALE; RAT; RECURRENT DISEASE; STATISTICS; TREATMENT OUTCOME;

ADULT; ANIMALS; BEHAVIOR THERAPY; COMBINED MODALITY THERAPY; CYCLOSERINE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMPLOSIVE THERAPY; OBSESSIVE-COMPULSIVE DISORDER; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 42449140233     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.2007.07050776     Document Type: Article

References (32)

1. Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, Huppert JD, Kjernisted K, Rowan V, Schmidt AB, Simpson HB, Tu X: Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 2005; 162:151-161
2. Simpson HB, Liebowitz MR, Foa EB, Kozak MJ, Schmidt AB, Rowan V, Petkova E, Kjernisted K, Huppert JD, Franklin ME, Davies SO, Campeas R: Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder. Depress Anxiety 2004; 19:225-233
3. Foa EB, Franklin ME, Moser J: Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination? Biol Psychiatry 2002; 52:987-997
4. Davis M, Myers KM: The role of glutamate and gamma-aminobutyric acid in fear extinction: clinical implications for exposure therapy. Biol Psychiatry 2002; 52:998-1007
5. Baker JD, Azorlosa JL: The NMDA antagonist MK-801 blocks the extinction of Pavlovian fear conditioning. Behav Neurosci 1996; 110:618-620
6. Royer S, Pare D: Bidirectional synaptic plasticity in intercalated amygdala neurons and the extinction of conditioned fear responses. Neuroscience 2002; 115:455-462
7. Cox J, Westbrook RF: The NMDA receptor antagonist MK-801 blocks acquisition and extinction of conditioned hypoalgesic responses in the rat. Q J Exp Psychol B 1994; 47:187-210
8. Fanselow MS, LeDoux JE: Why we think plasticity underlying Pavlovian fear conditioning occurs in the basolateral amygdala. Neuron 1999; 23:229-232
9. Goosens KA, Maren S: Long-term potentiation as a substrate for memory: evidence from studies of amygdaloid plasticity and Pavlovian fear conditioning. Hippocampus 2002; 12:592-599
10. Rogan MT, Staubli UV, LeDoux JE: Fear conditioning induces associative long-term potentiation in the amygdala. Nature 1997; 390:604-607
11. Davis M: Role of NMDA receptors and MAP kinase in the amygdala in extinction of fear: clinical implications for exposure therapy. Eur J Neurosci 2002; 16:395-398
12. Walker DL, Ressler KJ, Lu KT, Davis M: Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci 2002; 22:2343-2351
13. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, Hodges L, Davis M: Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004; 61:1136-1144
14. Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, Shiekh M, Otto MW: Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 2006; 63:298-304
15. Storch EA, Merlo LJ, Bengtson M, Murphy TK, Lewis MH, Yang MC, Jacob ML, Larson M, Hirsh A, Fernandez M, Geffken GR, Goodman WK: D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 2007; 22:230-237; correction, 22:312
16. Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, McCabe J, Peterson J, Foa EB: D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry 2007; 62:835-838
17. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS: The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry 1989; 46:1006-1011
18. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (4th ed, text revision). Washington, DC, APA, 2000
19. Kozak MJ, Foa EB: Mastery of Obsessive-Compulsive Disorder: A Cognitive-Behavioral Approach. San Antonio, Tex, Psychological Corporation, 1997
20. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCIDP, version 2.0). New York, New York State Psychiatric Institute Biometrics Research Department, 1995
21. Beck AT, Steer RA, Brown GK: Beck Depression Inventory, 2nd ed, Manual. San Antonio, Tex, Psychological Corporation, 1996
22. Boje KM, Wong G, Skolnick P: Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures. Brain Res 1993; 603:207-214
23. Ledgerwood L, Richardson R, Cranney J: Effects of D-cycloserine on extinction of conditioned freezing. Behav Neurosci 2003; 117:341-349
24. Goff DC, Herz L, Posever T, Shih V, Tsai G, Henderson DC, Freudenreich O, Evins AE, Yovel I, Zhang H, Schoenfeld D: A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl) 2005; 179:144-150
25. Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S, Stephanides M, Efferen TR, Angrist B, Peselow E, Corwin J, Gonzenbach S, Rotrosen JP: Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophr Res 2004; 71:239-248
26. Fakouhi TD, Jhee SS, Sramek JJ, Benes C, Schwartz P, Hantsburger G, Herting R, Swabb EA, Cutler NR: Evaluation of cycloserine in the treatment of Alzheimer's disease. J Geriatr Psychiatry Neurol 1995; 8:226-230
27. Tuominen HJ, Tiihonen J, Wahlbeck K: Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 2005; 72:225-234
28. Laake K, Oeksengaard AR: D-cycloserine for Alzheimer's disease. Cochrane Database Syst Rev 2002; CD003153
29. Quartermain D, Mower J, Rafferty MF, Herting RL, Lanthorn TH: Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol 1994; 257:7-12
30. Parnas AS, Weber M, Richardson R: Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem 2005; 83:224-231
31. Britton JC, Gold AL, Feczko EJ, Rauch SL, Williams D, Wright CI: D-cycloserine inhibits amygdala responses during repeated presentations of faces. CNS Spectr 2007; 12:600-605
32. Whittal ML, Thordarson DS, McLean PD: Treatment of obsessive-compulsive disorder: cognitive behavior therapy vs exposure and response prevention. Behav Res Ther 2005; 43:1559-1576